未登录

P

Pikalov, Andrei

sunovion pharmaceuticals inc.

H指数:0

被引数:5

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies

IF4.1

2023-04-140

OA

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies

EUROPEAN PSYCHIATRY

IF6.7

2021-05-107

OAAI

Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2020-12-0115

OAAI

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

利培酮治疗12个月后改用鲁拉西酮: 一项为期6个月的开放标签研究的结果

IF3.6

2020-05-0516

OAAI

Lurasidone in Post-Menopausal Females with Major Depressive Disorder with Mixed Features: Post-Hoc Analysis of a Placebo-Controlled Trial

Lurasidone在患有混合特征的重度抑郁症的绝经后女性中的应用: 安慰剂对照试验的事后分析

BIOLOGICAL PSYCHIATRY

IF9

2017-05-010

PREAI

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

lurasidone治疗患者的健康相关生活质量: 精神分裂症患者的switch试验结果

IF3.6

2014-02-239

OAAI